Is GRCE or GRFS more undervalued in 2026?

CirclFi compares Grace Therapeutics, Inc. (GRCE) and Grifols, S.A. (GRFS) using 13 institutional-grade valuation models. GRCE has a Quality of Company score of 4.5/10 while GRFS scores 1.7/10.

Which is a better buy — GRCE or GRFS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GRCE and GRFS valuations compare?

GRCE at $2.57 and GRFS at $7.85 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GRCE vs GRFS Valuation Comparison 2026 — Intrinsic Value Analysis

GRCE

Pharmaceutical Preparations

Grace Therapeutics, Inc.

Quality

4.5

out of 10

Value Trap

WARN

Price

$2.57

Last close

Models

7/13

Active

GRFS

Pharmaceutical Preparations

Grifols, S.A.

Quality

1.7

out of 10

Value Trap

—

Price

$7.85

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	GRCE Fair Value	GRCE Upside	GRFS Fair Value	GRFS Upside
Bayesian DCF	Intrinsic	$1.25	-51.3%	$2.40	-69.4%
Earnings Power Value	Intrinsic	—	—	$3.00	-62.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$4.06	+58.1%	$8.27	+5.4%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GRCE vs GRFS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GRCE vs GRFS — Which Stock Is More Undervalued?

GRCE scores higher with a 4.5/10 quality rating vs GRFS's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Grace Therapeutics, Inc. (GRCE) and Grifols, S.A. (GRFS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GRCE currently trades at $2.57 with a QOC of 4.5/10, while GRFS trades at $7.85 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).